The CHAMP phase 3 study shows strong safety and efficacy of NVK002 for the treatment of myopia.
Houman Hemmati, MD, PhD
Advertisement
Articles by Houman Hemmati, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
3D-printed contact lenses offer patient-specific fit in 20 minutes
2
First patient enrolled in pilot cataract trial assessing lanosterol eye drop ZOC2017217
3
Atropine, aspherical lenses enter trial for childhood myopia
4
The influence of the gut microbiome on eye health
5